Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BIKTARVY | Gilead Sciences | N-210251 RX | 2018-02-07 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYMTUZA | Johnson & Johnson | N-210455 RX | 2018-07-17 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GENVOYA | Gilead Sciences | N-207561 RX | 2015-11-05 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ODEFSEY | Gilead Sciences | N-208351 RX | 2016-03-01 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DESCOVY | Gilead Sciences | N-208215 RX | 2016-04-04 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VEMLIDY | Gilead Sciences | N-208464 RX | 2016-11-10 | 1 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
Expiration | Code | ||
---|---|---|---|
EMTRICITABINE / TENOFOVIR ALAFENAMIDE FUMARATE, DESCOVY, GILEAD SCIENCES INC | |||
2029-01-07 | ODE-457 | ||
2024-09-28 | ODE-284, ODE-285 | ||
BICTEGRAVIR SODIUM / EMTRICITABINE / TENOFOVIR ALAFENAMIDE FUMARATE, BIKTARVY, GILEAD SCIENCES INC | |||
2028-10-07 | ODE-378 | ||
2026-06-18 | ODE-256 | ||
2024-02-24 | M-82 | ||
TENOFOVIR ALAFENAMIDE FUMARATE, VEMLIDY, GILEAD SCIENCES INC | |||
2025-10-17 | NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods | |||
10786518 | 2038-07-19 | U-2978 | |
10039718 | 2032-10-06 | DP | |
8148374 | 2029-09-03 | DS, DP | U-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768 |
7700645 | 2026-12-26 | DS, DP | |
8518987 | 2024-02-16 | DS, DP | |
Bictegravir Sodium / Emtricitabine / Tenofovir Alafenamide Fumarate, Biktarvy, Gilead Sciences Inc | |||
10548846 | 2036-11-08 | DP | |
11744802 | 2036-11-08 | DP | |
9708342 | 2035-06-19 | DS, DP | |
10385067 | 2035-06-19 | U-257 | |
9216996 | 2033-12-19 | DS, DP | |
9732092 | 2033-12-19 | DS, DP | |
8754065 | 2032-08-15 | DS, DP | U-257, U-999, U-1259, U-1275, U-1663, U-2352, U-2765 |
9296769 | 2032-08-15 | DS, DP | U-257, U-999, U-1259, U-1275, U-1663, U-2352, U-2765 |
7390791 | 2025-04-17 | DS, DP | |
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc | |||
8633219 | 2030-04-30 | DP | U-257 |
9891239 | 2029-09-03 | DP | U-257 |
7635704 | 2026-10-26 | DS, DP | U-257 |
8981103 | 2026-10-26 | DS, DP | |
7176220 | 2026-08-27 | DS, DP | U-257 |
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Alafenamide Fumarate, Odefsey, Gilead Sciences Inc | |||
7125879 | 2025-04-21 | DS, DP | U-257 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 39 | 108 | 149 | 131 | 97 | 499 |
Hiv | D006678 | — | O98.7 | 27 | 22 | 40 | 74 | 47 | 204 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 19 | 47 | 23 | 50 | 52 | 186 |
Hepatitis b | D006509 | — | — | 8 | 16 | 11 | 20 | 17 | 70 |
Healthy volunteers/patients | — | — | — | 24 | — | — | 7 | 2 | 33 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 7 | 14 | 3 | 3 | 26 |
Hiv-1 | D015497 | — | — | 2 | 7 | 9 | 5 | — | 22 |
Infections | D007239 | EFO_0000544 | — | — | 6 | 9 | 3 | 3 | 21 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 3 | 3 | 2 | 3 | 4 | 15 |
Hepatitis c | D006526 | — | B19.2 | 3 | 2 | 1 | 4 | 4 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 2 | — | 6 | 8 |
Covid-19 | D000086382 | — | U07.1 | — | 3 | 5 | — | 2 | 7 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 1 | 3 |
Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | 1 | — | 1 | 2 |
Breast feeding | D001942 | — | — | — | — | 1 | — | 1 | 2 |
Sars-cov-2 | D000086402 | — | — | — | 1 | 2 | — | — | 2 |
Hiv seronegativity | D018023 | — | — | — | 1 | 1 | — | 1 | 2 |
Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | 1 | 2 |
B-cell lymphoma | D016393 | — | — | — | — | 1 | — | 1 | 2 |
Chronic hepatitis d | D019701 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis d | D003699 | EFO_0007304 | — | — | 4 | — | — | 1 | 5 |
Gender identity | D005783 | — | — | 1 | 1 | — | — | 3 | 4 |
Behavior and behavior mechanisms | D001520 | — | — | 1 | 1 | — | — | 2 | 3 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 1 | — | — | — | 2 |
Biliary liver cirrhosis | D008105 | — | K74.3 | — | 1 | — | — | 1 | 2 |
Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | 2 | — | — | — | 2 |
Parasitemia | D018512 | — | — | 1 | 1 | — | — | — | 1 |
Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | 1 | — | — | — | 1 |
Htlv-ii infections | D015491 | EFO_1001349 | — | — | 1 | — | — | — | 1 |
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Contraception behavior | D003268 | — | — | 1 | — | — | — | 1 | 2 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | 2 | — | — | — | — | 2 |
Heart disease risk factors | D000082742 | — | — | 1 | — | — | — | — | 1 |
Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | — | 1 |
Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
Transgenes | D019076 | — | — | 1 | — | — | — | — | 1 |
Hepacivirus | D016174 | — | — | 1 | — | — | — | — | 1 |
Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | 1 | — | — | — | — | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Risk reduction behavior | D040242 | — | — | — | — | — | — | 3 | 3 |
Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
Sustained virologic response | D000072230 | — | — | — | — | — | — | 2 | 2 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
Self efficacy | D020377 | — | — | — | — | — | — | 2 | 2 |
Pregnancy rate | D018873 | — | — | — | — | — | — | 2 | 2 |
Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
Job syndrome | D007589 | EFO_0003775 | D82.4 | — | — | — | — | 1 | 1 |
Drug common name | Tenofovir alafenamide |
INN | tenofovir alafenamide |
Description | Tenofovir alafenamide is an L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection. It has a role as an antiviral drug, a HIV-1 reverse transcriptase inhibitor and a prodrug. It is a L-alanine derivative, a phosphoramidate ester, an ether, a member of 6-aminopurines and an isopropyl ester. It is functionally related to an adenine. It is a conjugate base of a tenofovir alafenamide(1+). |
Classification | Small molecule |
Drug class | antivirals |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1 |
PDB | — |
CAS-ID | 379270-37-8 |
RxCUI | — |
ChEMBL ID | CHEMBL2107825 |
ChEBI ID | — |
PubChem CID | 9574768 |
DrugBank | DB09299 |
UNII ID | EL9943AG5J (ChemIDplus, GSRS) |